Danazol mediates collateral sensitivity via STAT3/Myc related pathway in multidrug-resistant cancer cells
Abstract Multidrug resistance presents an obstacle in cancer treatment. Among numerous combative strategies, collateral sensitivity (CS) drugs have opened a new avenue to defeat cancer by exploiting selective toxicity against multidrug-resistant (MDR) cancer. In the present study, a clinically used...
Enregistré dans:
Auteurs principaux: | Ying-Tzu Chang, Yu-Ning Teng, Kun-I Lin, Charles C. N. Wang, Susan L. Morris-Natschke, Kuo-Hsiung Lee, Chin-Chuan Hung |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2019
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/aadb4fb6502e4754853b555fcbdbf894 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Antibiotic collateral sensitivity is contingent on the repeatability of evolution
par: Daniel Nichol, et autres
Publié: (2019) -
Design principles of collateral sensitivity-based dosing strategies
par: Linda B. S. Aulin, et autres
Publié: (2021) -
Exploiting evolutionary steering to induce collateral drug sensitivity in cancer
par: Ahmet Acar, et autres
Publié: (2020) -
Collateral sensitivity constrains resistance evolution of the CTX-M-15 β-lactamase
par: Carola E. H. Rosenkilde, et autres
Publié: (2019) -
Low NCOR2 levels in multiple myeloma patients drive multidrug resistance via MYC upregulation
par: Tomoaki Mori, et autres
Publié: (2021)